Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Aclara BioSciences and Tokyo Metropolitan Institute

June 17th, 2004

Aclara BioSciences and Tokyo Metropolitan Institute

Abstract:
Aclara BioSciences Inc. and the Tokyo Metropolitan Institute of Medical Science (Rinshoken) announced today that they have entered into an agreement to collaborate on a study to evaluate breast cancer patient samples to validate candidate biomarkers detected with ACLARA's proprietary eTag(TM) technology. This study follows previously completed feasibility experiments on a small set of tissue samples from patients treated with Genentech's drug Herceptin(R) and chemotherapy.

Source:
Aclara BioSciences

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease February 22nd, 2018

Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B February 15th, 2018

Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT February 15th, 2018

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers February 15th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project